Download PDF
Klin Padiatr 2006; 218(3): 170-173
DOI: 10.1055/s-2006-933414
Sichelzellkrankheit

© Georg Thieme Verlag Stuttgart · New York

Genetische modulierende Faktoren der Klinik der homozygoten Sichelzellkrankheit

Genetic Modifiers of Homozygous Sickle Cell DiseaseK. Hartmann1 , A. E. Kulozik1
  • 1Universitätsklinik für Kinder- und Jugendmedizin, Pädiatrische Onkologie, Hämatologie und Immunologie, Heidelberg
Further Information

Publication History

Publication Date:
10 May 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die homozygote Sichelzellerkrankung (HbSS Krankheit) ist paradigmatisch für den komplexen Einfluss von genetisch modifizierenden Faktoren auf das klinische Bild einer monogenen Krankheit. Insbesondere beeinflusst die genetisch bedingte Variabilität der HbF-Konzentration die klinische Ausprägung der HbSS-Krankheit erheblich. Die erfolgreiche, mit einer verminderten Morbidität einhergehende medikamentöse Erhöhung der HbF-Konzentration zeigt, dass die Kenntnis der modulierenden genetischen Faktoren neue Möglichkeiten der therapeutischen Intervention eröffnen kann. In geringerem Maße lässt sich eine Assoziation von Schwere der Erkrankung und koinzident auftretender α-Thalassämie erkennen. Beide Faktoren, HbF und α-Thalassämie, können alleine die Vielfalt und Variabilität des klinischen Spektrums der HbSS-Krankheit nicht ausreichend erklären. Mit Methoden der Genomforschung wurden relevante Genloki identifiziert, die möglicherweise zur Abschätzung der Wahrscheinlichkeit des Auftretens schwerer Komplikationen der Sichelzellerkrankung wie etwa von Schlaganfällen genutzt werden können. Die subtile Analyse der genetisch modifizierenden Einflussfaktoren wird das Management von Patienten mit Sichelzellkrankheit nach dem Vorliegen von Ergebnissen prospektiver Studien somit voraussichtlich wesentlich beeinflussen.

Abstract

Homozygous sickle cell (HbSS) disease is paradigmatic for the complex influence of genetic modifiers of a monogenic disease. The genetically determined variability of HbF concentration has a strong impact on the clinical phenotype. The pharmacologically induced increase of HbF leads to a reduced morbidity which demonstrates that the knowledge of genetic modifiers enables the development of new therapeutic strategies. The presence of α-thalassemia also ameliorates the disease phenotype albeit not to the same extent as HbF does. Both factors, HbF and α-thalassemia are insufficient to explain the clinical variability of HbSS disease. The introduction of genome analysis has now provided the tools to identify relevant gene loci that will likely be helpful in estimating the probability of severe complications such as the occurrence of stroke. Following the validation in prospective studies, the subtle analysis of genetic modifiers will therefore influence the management of patients with sickle cell disease.

Schlüsselwörter

Sichelzellerkrankung - genetische Modulation - fetales Hämoglobin (HbF) - α-Thalassämie - single nucleotide polymorphism (SNP)

Key words

sickle cell disease - genetic modulation - fetal haemoglobin (HbF) - α-thalassemia - single nucleotide polymorphism (SNP)

Literatur

  • 1 Adams R J, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.  N Engl J Med. 2005;  353 2769-2778
    CrossrefPubMedGoogle Scholar
  • 2 Adams R J, Kutlar A, McKie V, Carl E, Nichols F T, Liu J C, McKie K, Clary A. Alpha thalassemia and stroke risk in sickle cell anemia.  Am J Hematol. 1994;  45 279-282
    PubMedGoogle Scholar
  • 3 Adedeji M O, Onuora V C, Ukoli F A. Haematological parameters associated with priapism in Nigerian patients with homozygous sickle cell disease.  J Trop Med Hyg. 1988;  91 157-159
    PubMedGoogle Scholar
  • 4 Adekile A D, Tuli M, Haider M Z, Al-Zaabi K, Mohannadi S, Owunwanne A. Influence of alpha-thalassemia trait on spleen function in sickle cell anemia patients with high HbF.  Am J Hematol. 1996;  53 1-5
    CrossrefPubMedGoogle Scholar
  • 5 Adekile A D, Yacoub F, Gupta R, Sinan T, Haider M Z, Habeeb Y, Al-Bloushi M, Moosa A. Silent brain infarcts are rare in Kuwaiti children with sickle cell disease and high Hb F.  Am J Hematol. 2002;  70 228-231
    CrossrefPubMedGoogle Scholar
  • 6 Bailey K, Morris J S, Thomas P, Serjeant G R. Fetal haemoglobin and early manifestations of homozygous sickle cell disease.  Arch Dis Child. 1992;  67 517-520
    PubMedGoogle Scholar
  • 7 Braden D S, Covitz W, Milner P F. Cardiovascular function during rest and exercise in patients with sickle-cell anemia and coexisting alpha thalassemia-2.  Am J Hematol. 1996;  52 96-102
    CrossrefPubMedGoogle Scholar
  • 8 Castro O, Brambilla D J, Thorington B, Reindorf C A, Scott R B, Gillette P, Vera J C, Levy P S. The Cooperative Study of Sickle Cell Disease . The acute chest syndrome in sickle cell disease: incidence and risk factors.  Blood. 1994;  84 643-649
    PubMedGoogle Scholar
  • 9 Charache S, Terrin M L, Moore R D, Dover G J, Barton F B, Eckert S V, McMahon R P, Bonds D R. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia . Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia.  N Engl J Med. 1995;  332 1317-1322
    CrossrefPubMedGoogle Scholar
  • 10 Condon P I, Marsh R J, Maude G H, Higgs D R, Weatherall D J, Serjeant G R. Alpha thalassaemia and the macular vasculature in homozygous sickle cell disease.  Br J Ophthalmol. 1983;  67 779-781
    PubMedGoogle Scholar
  • 11 De Ceulaer K, Serjeant G R. Acute splenic sequestration in Jamaican adults with homozygous sickle cell disease: a role of alpha thalassemia.  Br J Haematol. 1991;  77 563-564
    PubMedGoogle Scholar
  • 12 Dover G J, Boyer S H. Fetal hemoglobin-containing cells have the same mean corpuscular hemoglobin as cells without fetal hemoglobin: a reciprocal relationship between gamma- and beta-globin gene expression in normal subjects and in those with high fetal hemoglobin production.  Blood. 1987;  69 1109-1113
    PubMedGoogle Scholar
  • 13 Gladwin M T, Sachdev V, Jison M L, Shizukuda Y, Plehn J F, Minter K, Brown B, Coles W A, Nichols J S, Ernst I, Hunter L A, Blackwelder W C, Schechter A N, Rodgers G P, Castro O, Ognibene F P. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.  N Engl J Med. 2004;  350 886-895
    CrossrefPubMedGoogle Scholar
  • 14 Hawker H, Neilson H, Hayes R J, Serjeant G R. Haematological factors associated with avascular necrosis of the femoral head in homozygous sickle cell disease.  Br J Haematol. 1982;  50 29-34
    PubMedGoogle Scholar
  • 15 Hayes R J, Condon P I, Serjeant G R. Haematological factors associated with proliferative retinopathy in homozygous sickle cell disease.  Br J Ophthalmol. 1981;  65 29-35
    PubMedGoogle Scholar
  • 16 Higgs D R, Aldridge B E, Lamb J, Clegg J B, Weatherall D J, Hayes R J, Grandison Y, Lowrie Y, Mason K P, Serjeant B E, Serjeant G R. The interaction of alpha-thalassemia and homozygous sickle-cell disease.  N Engl J Med. 1982;  306 1441-1446
    PubMedGoogle Scholar
  • 17 Hoppe C, Klitz W, Cheng S, Apple R, Steiner L, Robles L, Girard T, Vichinsky E, Styles L. Gene interactions and stroke risk in children with sickle cell anemia.  Blood. 2004;  103 2391-2396
    CrossrefPubMedGoogle Scholar
  • 18 Hsu L L, Miller S T, Wright E, Kutlar A, McKie V, Wang W, Pegelow C H, Driscoll C, Hurlet A, Woods G, Elsas L, Embury S, Adams R J. Alpha Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia.  J Pediatr Hematol Oncol. 2003;  25 622-628
    CrossrefPubMedGoogle Scholar
  • 19 Kar B C, Satapathy R K, Kulozik A E, Kulozik M, Sirr S, Serjeant B E, Serjeant G R. Sickle cell disease in Orissa State, India.  Lancet. 1986;  2 1198-1201
    PubMedGoogle Scholar
  • 20 Koshy M, Entsuah R, Koranda A, Kraus A P, Johnson R, Bellvue R, Flournoy-Gill Z, Levy P. Leg ulcers in patients with sickle cell disease.  Blood. 1989;  74 1403-1408
    PubMedGoogle Scholar
  • 21 Kulozik A E, Kar B C, Satapathy R K, Serjeant B E, Serjeant G R, Weatherall D J. Fetal hemoglobin levels and beta (s) globin haplotypes in an Indian populations with sickle cell disease.  Blood. 1987;  69 1742-1746
    PubMedGoogle Scholar
  • 22 Kulozik A E, Kar B C, Serjeant G R, Serjeant B E, Weatherall D J. The molecular basis of alpha thalassemia in India. Its interaction with the sickle cell gene.  Blood. 1988;  71 467-472
    PubMedGoogle Scholar
  • 23 Kulozik A E, Wainscoat J S, Serjeant G R, Kar B C, Al-Awamy B, Essan G J, Falusi A G, Haque S K, Hilali A M, Kate S. et al . Geographical survey of beta S-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation.  Am J Hum Genet. 1986;  39 239-244
    PubMedGoogle Scholar
  • 24 Labie D, Pagnier J, Lapoumeroulie C, Rouabhi F, Dunda-Belkhodja O, Chardin P, Beldjord C, Wajcman H, Fabry M E, Nagel R L. Common haplotype dependency of high G gamma-globin gene expression and high HbF levels in beta-thalassemia and sickle cell anemia patients.  Proc Natl Acad Sci U S A. 1985;  82 2111-2114
    PubMedGoogle Scholar
  • 25 Miller S T, Sleeper L A, Pegelow C H, Enos L E, Wang W C, Weiner S J, Wethers D L, Smith J, Kinney T R. Prediction of adverse outcomes in children with sickle cell disease.  N Engl J Med. 2000;  342 83-89
    CrossrefPubMedGoogle Scholar
  • 26 Morris J S, Dunn D T, Poddar D, Serjeant G R. Haematological risk factors for pregnancy outcome in Jamaican women with homozygous sickle cell disease.  Br J Obstet Gynaecol. 1994;  101 770-773
    PubMedGoogle Scholar
  • 27 Mukherjee M B, Surve R, Tamankar A, Gangakhedkar R R, Ghosh K, Lu C Y, Krishnamoorthy R, Colah R, Mohanty D. The influence of alpha-thalassaemia on the haematological & clinical expression of sickle cell disease in western India.  Indian J Med Res. 1998;  107 178-181
    PubMedGoogle Scholar
  • 28 Neonato M G, Guilloud-Bataille M, Beauvais P, Begue P, Belloy M, Benkerrou M, Ducrocq R, Maier-Redelsperger M, de Montalembert M, Quinet B, Elion J, Feingold J, Girot R. French Study Group on Sickle Cell Disease . Acute clinical events in 299 homozygous sickle cell patients living in France.  Eur J Haematol. 2000;  65 155-164
    CrossrefPubMedGoogle Scholar
  • 29 Neu-Yilik G, Kulozik A E. mRNA Metabolism and hereditary disorders: a tale of surveillance and escape.  Klin Padiatr. 2004;  216 304-314
    PubMedGoogle Scholar
  • 30 Nolan V G, Wyszynski D F, Farrer L A, Steinberg M H. Hemolysis-associated priapism in sickle cell disease.  Blood. 2005;  106 3264-3267
    CrossrefPubMedGoogle Scholar
  • 31 Ohene-Frempong K, Weiner S J, Sleeper L A, Miller S T, Embury S, Moohr J W, Wethers D L, Pegelow C H, Gill F M. Cerebrovascular accidents in sickle cell disease: rates and risk factors.  Blood. 1998;  91 288-294
    PubMedGoogle Scholar
  • 32 Platt O S, Brambilla D J, Rosse W F, Milner P F, Castro O, Steinberg M H, Klug P P. Mortality in sickle cell disease. Life expectancy and risk factors for early death.  N Engl J Med. 1994;  330 1639-1644
    CrossrefPubMedGoogle Scholar
  • 33 Platt O S, Thorington B D, Brambilla D J, Milner P F, Rosse W F, Vichinsky E, Kinney T R. Pain in sickle cell disease. Rates and risk factors.  N Engl J Med. 1991;  325 11-16
    CrossrefPubMedGoogle Scholar
  • 34 Schwarz C, Vetter B, Kohne E, Kulozik A E. Beta thalassemia in Germany: molecular genetics and clinical phenotype in immigrant and in the native population.  Klin Padiatr. 1997;  209 172-177
    PubMedGoogle Scholar
  • 35 Sebastiani P, Ramoni M F, Nolan V, Baldwin C T, Steinberg M H. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia.  Nat Genet. 2005;  37 435-440
    CrossrefPubMedGoogle Scholar
  • 36 Sharan K, Surrey S, Ballas S, Borowski M, Devoto M, Wang K F, Sandler E, Keller M. Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease.  Br J Haematol. 2004;  124 240-243
    CrossrefPubMedGoogle Scholar
  • 37 Steinberg M H, Barton F, Castro O, Pegelow C H, Ballas S K, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.  Jama. 2003;  289 1645-1651
    CrossrefPubMedGoogle Scholar
  • 38 Steinberg M H, Embury S H. Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene.  Blood. 1986;  68 985-990
    PubMedGoogle Scholar
  • 39 Steinberg M H, Rosenstock W, Coleman M B, Adams J G, Platica O, Cedeno M, Rieder R F, Wilson J T, Milner P, West S. Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia.  Blood. 1984;  63 1353-1360
    PubMedGoogle Scholar
  • 40 Tang D C, Prauner R, Liu W, Kim K H, Hirsch R P, Driscoll M C, Rodgers G P. Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study.  Am J Hematol. 2001;  68 164-169
    CrossrefPubMedGoogle Scholar
  • 41 Taylor J G, Tang D C, Savage S A, Leitman S F, Heller S I, Serjeant G R, Rodgers G P, Chanock S J. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease.  Blood. 2002;  100 4303-4309
    CrossrefPubMedGoogle Scholar
  • 42 Thomas P W, Higgs D R, Serjeant G R. Benign clinical course in homozygous sickle cell disease: a search for predictors.  J Clin Epidemiol. 1997;  50 121-126
    CrossrefPubMedGoogle Scholar
  • 43 Wali Y A, Al-Lamki Z, Hussein S S, Bererhi H, Kumar D, Wasifuddin S, Zachariah M, Ghosh K. Splenic function in Omani children with sickle cell disease: correlation with severity index, hemoglobin phenotype, iron status, and alpha-thalassemia trait.  Pediatr Hematol Oncol. 2002;  19 491-500
    CrossrefPubMedGoogle Scholar
  • 44 Wang W C, Morales K H, Scher C D, Styles L, Olivieri N, Adams R, Brambilla D. Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.  J Pediatr. 2005;  147 244-247
    PubMedGoogle Scholar
  • 45 Zimmerman S A, Ware R E. Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease.  Am J Hematol. 1998;  59 267-272
    CrossrefPubMedGoogle Scholar

Kathrin Hartmann

Universitätsklinik für Kinder- und Jugendmedizin, Pädiatrische Onkologie, Hämatologie und Immunologie

Im Neuenheimer Feld 153

69120 Heidelberg

Email: Kathrin.Hartmann@med.uni-heidelberg.de

      >